A Study to Evaluate the Pharmacokinetics, Safety, and Tolerability of Single Ascending Doses of ABBV-1451 Infusions and Injections in Healthy Adult Participants

Part of paid clinical trials in Grayslake, Illinois.

Sponsor
AbbVie
Study ID
NCT07570147
Phase
PHASE1
Status
Recruiting
Apply to this trial

Conditions

  • Healthy Volunteer

Eligibility Criteria

Sex
ALL
Age
18 Years - 60 Years
Healthy Volunteers
Accepted

Interventions

  • ABBV-1451 — DRUG
    Injection
  • ABBV-1451 — DRUG
    Infusion
  • Placebo — OTHER
    Injection
  • Placebo — OTHER
    Infusion

Study Details

The objective of this study is to assess the pharmacokinetic (PK), immunogenicity, safety, and tolerability of ABBV-1451 after single ascending doses in healthy adult volunteers.

Key Dates

Start date
May 1, 2026
Status verified
May 2026
Primary completion
Apr 30, 2027
Completion
Apr 30, 2027

Study Design

Enrollment
90 participants (estimated)
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
BASIC_SCIENCE

Arms

  • Experimental: Part 1: Group 1
    Participants will receive either single ascending doses of ABBV-1451 until they reach Dose A or placebo.
  • Experimental: Part 1: Group 2
    Participants will receive either single ascending doses of ABBV-1451 until they reach Dose B or placebo.
  • Experimental: Part 1: Group 3
    Participants will receive either single ascending doses of ABBV-1451 until they reach Dose C or placebo.
  • Experimental: Part 1: Group 4
    Participants will receive either single ascending doses of ABBV-1451 until they reach Dose A or placebo.
  • Experimental: Part 1: Group 5
    Participants will receive either single ascending doses of ABBV-1451 until they reach Dose C or placebo.
  • Experimental: Part 1: Group 6
    Participants will receive either single ascending doses of ABBV-1451 until they reach Dose TBD or placebo.
  • Experimental: Part 2: Group 7
    Japanese participants will receive a single dose of ABBV-1451 Dose C or placebo.
  • Experimental: Part 2: Group 8
    Han Chinese participants will receive a single dose of ABBV-1451 Dose C or placebo.

Primary Outcome Measure

Number of Participants with Adverse Events (AEs) [ Time Frame: Up to Approximately Day 211 ]

Central Contacts

Locations (1)

FacilityCityStateZIPSite coordinators
Acpru /Id# 282128GrayslakeIllinois60030-

Find similar trials in Grayslake, IL

By research site
Acpru· Grayslake, IL

Related Studies